<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732483</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0031</org_study_id>
    <nct_id>NCT02732483</nct_id>
  </id_info>
  <brief_title>Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrointestinal(GI) hemorrhage related with gastric cancer is prevalent in advanced cases
      mostly. As endoscopic hemostatic methods such as argon plasma ablation (APC) had developed,
      controlling GI hemorrhage in gastric cancer is much easier these days. but re-bleeding rate
      is still high, even after successful hemostasis with APC or electrical coagulation.
      Furthermore patients who were experienced re-bleeding are expected poorer survival outcomes
      than those who are not. So excellent bleeding control in gastric cancer is most important in
      GI hemorrhage of gastric cancer.

      Recently developed hemostatic powder [Endo-Clot(TM)] is easy to use and have proven its
      usefulness in GI hemorrhage in peptic ulcer diseases. So in this study, investigator will try
      to find out feasibility &amp; safety of Endo-Clot(TM) in GI hemorrhage in gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rebleeding rate</measure>
    <time_frame>within 30 days</time_frame>
    <description>Proportion of patients who are experience rebleeding events after hemostasis within 30 days expected to be lower than 10 %.
Definition rebleeding events 1. Overt symptoms of GI bleeding(such as hematemesis, melena) and/or Hemoglobin down more than 2g/dl compared to Hemoglobin level which were checked just after procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success of bleeding control rate</measure>
    <time_frame>within 2 weeks and 4 weeks</time_frame>
    <description>Proportion of patients who are experience successful hemostasis is expected to be higher than 80 %applying Endo-Clot™, Rebleeding rate in 3days, rate of additional intervention other than initial endoscopic hemostasis, Mortalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebleeding rate</measure>
    <time_frame>in 3 days</time_frame>
    <description>Proportion of patients experience rebleeding events after hemostasis within 3 days expected to be lower than 5 %. Definition of Rebleeding rate in 3days 1. Overt symptoms of GI bleeding(such as hematemesis, melena) and/or Hemoglobin down more than 2g/dl compared to Hemoglobin level which were checked just after procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of additional intervention other than initial endoscopic hemostasis</measure>
    <time_frame>within 2 weeks to 4 weeks</time_frame>
    <description>Definition of Successful hemostasis; controlled bleeding vessel in 5 minute after applying Endo-Clot™</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortalities</measure>
    <time_frame>within 2 weeks to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Bleeding at Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Endo-Clot(TM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endo-Clot(TM)</intervention_name>
    <description>The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)</description>
    <arm_group_label>Endo-Clot(TM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 19 and less 80 yeas old

          -  Gastric cancer was diagnosed with biopsy and/or computed tomography

          -  Endoscopic hemostasis is needed upto GI hemorrhage

          -  Endoscopic examination is available in 24hours

          -  ECOG performance status(PS) &lt;2

        Exclusion Criteria:

          -  Double primary caner

          -  Hypersensitivity of hemostatic power[Endo-Clot(TM)]

          -  Variceal bleeding or benign gastric ulcer bleeding

          -  Hemodynamically unstable with low systolic BP&lt;90mmHg and/or tachycardia PR&gt;120bpm

          -  endoscopic hemostasis within 7 days before screening

          -  Contraindication for endoscopic examination

          -  Pregnant

          -  Breast feeding

          -  bleeding tendency with low platelet count &lt;50,000 /mm^3 and/or INR&gt;2

          -  Bacterial infection with needs for antibiotics therapy

          -  Unavailable to discontinue anti-coagulation agent for 3days

          -  Vascular shunt

          -  Cardiovascular and/or pulmonary diseases

          -  Active hepatitis or severe liver diseases

          -  Renal dysfunction

          -  Bone marrow dysfunction

          -  Neurologic deficit and/or psychotic feature

          -  Unavailable informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Chul Park, MD</last_name>
    <phone>+ 82-2-2228-2272</phone>
    <email>JUNCHUL75@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine,</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Chul Park, MD</last_name>
      <phone>+ 82-2-2228-2272</phone>
      <email>JUNCHUL75@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Thrumurthy SG, Chaudry MA, Hochhauser D, Mughal M. The diagnosis and management of gastric cancer. BMJ. 2013 Nov 4;347:f6367. doi: 10.1136/bmj.f6367. Review.</citation>
    <PMID>24191271</PMID>
  </results_reference>
  <results_reference>
    <citation>Chaw CL, Niblock PG, Chaw CS, Adamson DJ. The role of palliative radiotherapy for haemostasis in unresectable gastric cancer: a single-institution experience. Ecancermedicalscience. 2014 Jan 10;8:384. doi: 10.3332/ecancer.2014.384. eCollection 2014.</citation>
    <PMID>24482669</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer. 2002;5(3):177-82. Review.</citation>
    <PMID>12378346</PMID>
  </results_reference>
  <results_reference>
    <citation>Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y, Kaminishi M. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011 Oct;14(4):301-16. doi: 10.1007/s10120-011-0085-6. Epub 2011 Sep 7.</citation>
    <PMID>21894577</PMID>
  </results_reference>
  <results_reference>
    <citation>Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. 2014 May;34(5):2079-85. Review.</citation>
    <PMID>24778009</PMID>
  </results_reference>
  <results_reference>
    <citation>Romera Barba E, Castañer Ramón-Llín J, Sánchez Pérez A, García Marcilla JA, Vázquez Rojas JL. Transcatheter arterial embolization in the management of acute bleeding from advanced gastric cancer. Cir Esp. 2014 Aug-Sep;92(7):492-4. doi: 10.1016/j.ciresp.2013.11.004. Epub 2013 Dec 27. English, Spanish.</citation>
    <PMID>24378191</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, Buxbaum J, Laine L. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. Aliment Pharmacol Ther. 2013 Jul;38(2):144-50. doi: 10.1111/apt.12347. Epub 2013 May 28.</citation>
    <PMID>23710797</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim YI, Choi IJ, Cho SJ, Lee JY, Kim CG, Kim MJ, Ryu KW, Kim YW, Park YI. Outcome of endoscopic therapy for cancer bleeding in patients with unresectable gastric cancer. J Gastroenterol Hepatol. 2013 Sep;28(9):1489-95. doi: 10.1111/jgh.12262.</citation>
    <PMID>23662891</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421-7.</citation>
    <PMID>17899453</PMID>
  </results_reference>
  <results_reference>
    <citation>Hashimoto K, Mayahara H, Takashima A, Nakajima TE, Kato K, Hamaguchi T, Ito Y, Yamada Y, Kagami Y, Itami J, Shimada Y. Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol. 2009 Aug;135(8):1117-23. doi: 10.1007/s00432-009-0553-0. Epub 2009 Feb 10.</citation>
    <PMID>19205735</PMID>
  </results_reference>
  <results_reference>
    <citation>Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N, Nishimura T. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol. 2011 Jan;137(1):125-30. doi: 10.1007/s00432-010-0866-z. Epub 2010 Mar 25.</citation>
    <PMID>20336314</PMID>
  </results_reference>
  <results_reference>
    <citation>Tey J, Choo BA, Leong CN, Loy EY, Wong LC, Lim K, Lu JJ, Koh WY. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine (Baltimore). 2014 Nov;93(22):e118. doi: 10.1097/MD.0000000000000118.</citation>
    <PMID>25396330</PMID>
  </results_reference>
  <results_reference>
    <citation>Ono S, Ono M, Nakagawa M, Shimizu Y, Kato M, Sakamoto N. Delayed bleeding and hemorrhage of mucosal defects after gastric endoscopic submucosal dissection on second-look endoscopy. Gastric Cancer. 2016 Apr;19(2):561-7. doi: 10.1007/s10120-015-0507-y. Epub 2015 Jun 19.</citation>
    <PMID>26089283</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim SB, Lee SH, Kim KO, Jang BI, Kim TN, Jeon SW, Kwon JG, Kim EY, Jung JT, Park KS, Cho KB, Kim ES, Kim HJ, Park CK, Park JB, Yang CH. Risk Factors Associated with Rebleeding in Patients with High Risk Peptic Ulcer Bleeding: Focusing on the Role of Second Look Endoscopy. Dig Dis Sci. 2016 Feb;61(2):517-22. doi: 10.1007/s10620-015-3846-y. Epub 2015 Aug 22.</citation>
    <PMID>26297133</PMID>
  </results_reference>
  <results_reference>
    <citation>Bustamante-Balén M, Plumé G. Role of hemostatic powders in the endoscopic management of gastrointestinal bleeding. World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):284-92. doi: 10.4291/wjgp.v5.i3.284. Review.</citation>
    <PMID>25133029</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang R, Pan Y, Hui N, Guo X, Zhang L, Wang X, Zhang R, Luo H, Zhou X, Tao Q, Liu Z, Wu K. Polysaccharide hemostatic system for hemostasis management in colorectal endoscopic mucosal resection. Dig Endosc. 2014 Jan;26(1):63-8. doi: 10.1111/den.12054. Epub 2013 Mar 31.</citation>
    <PMID>23551344</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>bleeding</keyword>
  <keyword>gastrointestinal hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

